RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2009; 101(01): 12-13
DOI: 10.1160/TH08-11-0745
DOI: 10.1160/TH08-11-0745
Editorial Focus
Another view on prasugrel
Weitere Informationen
Publikationsverlauf
Received:
14. November 2008
Accepted:
14. November 2008
Publikationsdatum:
23. November 2017 (online)
-
References
- 1 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
- 2 De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
- 3 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
- 4 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
- 5 Serebruany V, Shalito I, Kopyleva O. Prasugrel development: Claims and achievements. Thromb Haemost 2008; 101: 14-22.
- 6 Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-2081.
- 7 Serebruany VL. Prasugrel, clopidogrel, and combining Swedish apples with American oranges. Eur Heart J 2006; 27: 1886-1887.
- 8 Serebruany VL, Midei MG, Meilman H. et al. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract 2006; 60: 863-866.
- 9 Serebruany V. Prasugrel versus clopidogrel. N Engl J Med 2008; 358: 1298.
- 10 Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovasc Dis 2008; 26: 93-94.
- 11 Serebruany VL. Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). Am J Cardiol 2008; 101: 1364-1366.
- 12 Serebruany VL. Bleeding risks with prasugrel in the TRITON trial: Good news ... bad news. Cardiology 2008; 111: 265-267.
- 13 Pasceri V, Patti G, Di Sciascio G. Prasugrel versus clopidogrel. N Engl J Med 2008; 358: 1298-1299.
- 14 Ramaraj R. Intensive antiplatelet therapy for reduction of ischaemic events. Lancet 2008; 372: 531.
- 15 Wiviott SD, Braunwald E, Murphy SA. et al. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Am J Cardiol 2008; 101: 1367-1370.
- 16 Wiviott SD, Braunwald E, Antman EM. Author Reply. N Engl J Med 2008; 358: 1299-1301.
- 17 Wiviott SD, Braunwald E, Murphy SA. et al. Author Reply. Lancet 2008; 372: 532.
- 18 Jernberg T, Wallentin L. Prasugrel, clopidogrel, and combining Swedish apples with American oranges: reply. Eur Heart J 2006; 27: 1887-1888.